Role of CRISPR-Cas9 in Understanding, Modelling, and Treating Cancer
DOI:
https://doi.org/10.70749/ijbr.v3i6.1599Keywords:
CRISPR-CAS9, Cancer, Genome Editing Technique, Oncology, Genome Engineering, Gene EditingAbstract
Background: Cancer is a genetic disease resulting from cumulative genetic/epigenetic aberrations. The genome editing technique known as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 has been widely used for effective gene disruption and modification in a variety of cell types and organisms, both in vitro and in vivo. Cancer treatment using CRISPR-Cas9 has showed a lot of promise. Objective: To synthesize current knowledge on the understanding, modeling and treatment of Cancer through CRISPR-Cas9 technique. To delineate about the role of CRISPR-Cas9 in understanding, modeling and treating cancer. Cancer disease, explore the genetic and environmental factors contributing to it, and assess the potential of novel therapeutic approaches like CRISPR-Cas9 towards it. Methods: A narrative review was conducted through a structured search of PubMed, Scopus, Web of Science, and Google Scholar, focusing on articles published on role of CRISPR-Cas9 on cancer. Keywords related to CRISPR-Cas9 and its implications across cancer were used to identify relevant studies. Inclusion criteria targeted original research, reviews, and meta-analyses published in English that contributed to CRISPR-CAS9 role in cancer understanding, modeling and treatment. Data extraction and synthesis were performed to highlight key findings, mechanisms, and therapeutic strategies. Results: The review emphasizes the critical role of CRISPR-Cas9 in understanding, modeling and treatment of cancer in the wide range. It identifies CRISPR-Cas9 contributing to the treatment of cancer and highlights it has very important role in treating it. Additionally, the review explores emerging therapies. Conclusion: The genetic mutations and environmental influences contributing to the cancer and progression. CRISPR-Cas9 has a pivotal role in the treatment of cancer. Understanding the complex mechanisms and working for proper treatment of cancer through it is very essential for devising effective treatment. While significant advances have been made, further research is needed to fully exploit the therapeutic potential of targeting cancer through a gene editing tool like CRISPR-Cas9.
Downloads
References
Adamiec-Organisciok, M., Wegrzyn, M., Cienciala, L., Magate, N., Skonieczna, M., & Nackiewicz, J. (2024). Resistance to death pathway induction as a potential targeted therapy in CRISPR/Cas-9 knock-out colorectal cancer cell lines. Gastroenterology Review/Przegląd Gastroenterologiczny, 19(2), 112-120.
https://doi.org/10.5114/pg.2024.134872
Adamiec-Organisciok, M., Wegrzyn, M., Cienciala, L., Magate, N., Skonieczna, M., & Nackiewicz, J. (2024). Resistance to death pathway induction as a potential targeted therapy in CRISPR/Cas-9 knock-out colorectal cancer cell lines. Gastroenterology Review/Przegląd Gastroenterologiczny, 19(2), 112-120.
https://doi.org/10.5114/pg.2024.134872
Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., & Liu, D. R. (2019). Search-and-replace Genome Editing without double-strand Breaks or Donor DNA. Nature, 576(576).
https://doi.org/10.1038/s41586-019-1711-4
Mengstie, M. A., Azezew, M. T., Dejenie, T. A., Teshome, A. A., Admasu, F. T., Teklemariam, A. B., Mulu, A. T., Agidew, M. M., Adugna, D. G., Geremew, H., & Abebe, E. C. (2024). Recent Advancements in Reducing the Off-Target Effect of CRISPR-Cas9 Genome Editing. Biologics: Targets and Therapy, 18(1), 21–28.
https://doi.org/10.2147/BTT.S429411
Ayanoglu, F. B. (2020). Bioethical Issues in Genome Editing by the CRISPR/Cas9 Technology. Turkish Journal of Biology, 44(2), 110–120.
https://doi.org/10.3906/biy-1912-52
Barrangou, R., Coûté-Monvoisin, A.-C., Stahl, B., Chavichvily, I., Damange, F., Romero, Dennis A., Boyaval, P., Fremaux, C., & Horvath, P. (2013). Genomic impact of CRISPR immunization against bacteriophages. Biochemical Society Transactions, 41(6), 1383–1391.
https://doi.org/10.1042/bst20130160
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science (New York, N.Y.), 315(5819), 1709–1712.
https://doi.org/10.1126/science.1138140
Bayat, M., & Javid Sadri Nahand. (2024). Let’s make it personal: CRISPR tools in manipulating cell death pathways for cancer treatment. Cell Biology and Toxicology, 40(1).
https://doi.org/10.1007/s10565-024-09907-z
Benci, J. L., Johnson, L. R., Choa, R., Xu, Y., Qiu, J., Zhou, Z., ... & Minn, A. J. (2019). Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade. Cell, 178(4), 933-948.
https://www.cell.com/cell/fulltext/S0092-8674(19)30784-6
Bhat, K. P., Vijay, J., Vilas, C. K., Asundi, J., Zou, J., Lau, T., Cai, X., Ahmed, M., Kabza, M., Weng, J., Fortin, J.-P., Lun, A., Durinck, S., Hafner, M., Costa, M. R., & Ye, X. (2024). CRISPR activation screens identify the SWI/SNF ATPases as suppressors of ferroptosis. Cell Reports, 43(6), 114345–114345.
https://doi.org/10.1016/j.celrep.2024.114345
Boland, J., & Nedelcu, E. (2020). CRISPR/Cas9 for the Clinician: Current uses of gene editing and applications for new therapeutics in oncology. The Permanente Journal, 24, 20-040.
https://doi.org/10.7812/TPP/20.040
Bonato, A., Bomben, R., Chakraborty, S., Felician, G., Martines, C., Zucchetto, A., Chiarenza, A., Poeta, G. D., Marasca, R., Tafuri, A., Laurenti, L., Dimovski, A. J., Gattei, V., & Efremov, D. G. (2021). Chronic Lymphocytic Leukemia Cells with Mutated Nfkbie Are Positively Selected By Microenvironmental Signals and Display Reduced Sensitivity to Ibrutinib Treatment. Blood, 138(Supplement 1), 248–248.
https://doi.org/10.1182/blood-2021-149442
Chen, F., Alphonse, M., & Liu, Q. (2020). Strategies for nonviral nanoparticle‐based delivery of CRISPR/Cas9 therapeutics. WIREs Nanomedicine and Nanobiotechnology, 12(3).
https://doi.org/10.1002/wnan.1609
Cheung, A. H.-K., Chow, C., Zhang, J., Zhou, Y., Huang, T., Ng, K. C.-K., Or, T. C.-T., Yao, Y. Y., Dong, Y., Fung, J. M.-W., Xiong, L., Chan, A. K.-Y., Lung, W.-M. R., Kang, W., & To, K.-F. (2018). Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9. Laboratory Investigation; a Journal of Technical Methods and Pathology, 98(7), 968–976.
https://doi.org/10.1038/s41374-018-0056-1
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., & Zhang, F. (2013). Multiplex Genome Engineering Using CRISPR/Cas Systems. Science, 339(6121), 819–823.
https://doi.org/10.1126/science.1231143
Cordeiro, A., Deveau, A. P., Dhanraj, S., Dror, Y., & Berman, J. (2019). Characterizing Dyskeratosis Congenita Caused By Parn Mutations in the Zebrafish. Blood, 134(Supplement_1), 3744–3744.
https://doi.org/10.1182/blood-2019-130147
Cornell, L., Wander, S. A., Visal, T., Wagle, N., & Shapiro, G. I. (2019). MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance. Cell Reports, 26(10), 2667-2680.e7.
https://doi.org/10.1016/j.celrep.2019.02.023
Cross, D., & Burmester, J. K. (2006). Gene Therapy for Cancer Treatment: Past, Present and Future. Clinical Medicine & Research, 4(3), 218–227.
https://doi.org/10.3121/cmr.4.3.218
Cursons, J., Souza-Fonseca-Guimaraes, F., Foroutan, M., Anderson, A., Hollande, F., Hediyeh-Zadeh, S., ... & Davis, M. J. (2019). A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients. Cancer immunology research, 7(7), 1162-1174.
https://doi.org/10.1158/2326-6066.CIR-18-0500
D’SOUZA, R. U. S. S. E. L. L., MathEw, M., & SuRapanEni, K. M. (2023). A Scoping Review on the Ethical Issues in the Use of CRISPR-Cas9 in the Creation of Human Disease Models. Journal of Clinical & Diagnostic Research, 17(12).
https://doi.org/10.7860/JCDR/2023/68275.18809
Moffat, J., Komor, A. C., & Lum, L. (2024). Impact of CRISPR in cancer drug discovery. Science, 386(6720), 378–379.
https://doi.org/10.1126/science.adi6884
Floc’h, N., Martin, M. J., Riess, J. W., Orme, J. P., Staniszewska, A. D., Ménard, L., Cuomo, M. E., O’Neill, D. J., Ward, R. A., Finlay, R. V., McKerrecher, D., Cheng, M., Vang, D. P., Burich, R. A., Keck, J. G., Gandara, D. R., Mack, P. C., & Cross, D. A. E. (2018). Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Molecular Cancer Therapeutics, 17(5), 885–896.
https://doi.org/10.1158/1535-7163.mct-17-0758
Freeman, A. J., Vervoort, S. J., Ramsbottom, K. M., Kelly, M. J., Michie, J., Pijpers, L., Johnstone, R. W., Kearney, C. J., & Oliaro, J. (2019). Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion. Cell Reports, 28(11), 2784-2794.e5.
https://doi.org/10.1016/j.celrep.2019.08.017
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017). Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature, 551(7681), 464–471.
https://doi.org/10.1038/nature24644
Grünewald, J., Zhou, R., Garcia, S. P., Iyer, S., Lareau, C. A., Aryee, M. J., & Joung, J. K. (2019). Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature, 569(7756), 433–437.
https://doi.org/10.1038/s41586-019-1161-z
Harris, R. S., Petersen-Mahrt, S. K., & Neuberger, M. S. (2002). RNA Editing Enzyme APOBEC1 and Some of Its Homologs Can Act as DNA Mutators. Molecular Cell, 10(5), 1247–1253.
https://doi.org/10.1016/s1097-2765(02)00742-6
Hazafa, A., Mumtaz, M., Farooq, M. F., Bilal, S., Chaudhry, S. N., Firdous, M., Naeem, H., Ullah, M. O., Yameen, M., Mukhtiar, M. S., & Zafar, F. (2020). CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions. Life Sciences, 263, 118525.
https://doi.org/10.1016/j.lfs.2020.118525
Hille, F., & Charpentier, E. (2016). CRISPR-Cas: biology, mechanisms and relevance. Philosophical Transactions of the Royal Society B: Biological Sciences, 371(1707), 20150496.
https://doi.org/10.1098/rstb.2015.0496
Horvath, P., & Barrangou, R. (2010). CRISPR/Cas, the Immune System of Bacteria and Archaea. Science, 327(5962), 167–170.
https://doi.org/10.1126/science.1179555
Ihry, R. J., Worringer, K. A., Salick, M. R., Frias, E., Ho, D., Theriault, K., Kommineni, S., Chen, J., Sondey, M., Ye, C., Randhawa, R., Kulkarni, T., Yang, Z., McAllister, G., Russ, C., Reece-Hoyes, J., Forrester, W., Hoffman, G. R., Dolmetsch, R., & Kaykas, A. (2018). p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. Nature Medicine, 24(7), 939–946.
https://doi.org/10.1038/s41591-018-0050-6
Ishii, T. (2015). Germ line genome editing in clinics: the approaches, objectives and global society. Briefings in Functional Genomics, 16(1), 46–56.
https://doi.org/10.1093/bfgp/elv053
Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., & Nakata, A. (1987). Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. Journal of Bacteriology, 169(12), 5429–5433.
https://doi.org/10.1128/jb.169.12.5429-5433.1987
Jansen, Ruud., Embden, Jan. D. A. van, Gaastra, Wim., & Schouls, Leo. M. (2002). Identification of genes that are associated with DNA repeats in prokaryotes. Molecular Microbiology, 43(6), 1565–1575.
https://doi.org/10.1046/j.1365-2958.2002.02839.x
Jiang, F., & Doudna, J. A. (2017). CRISPR–Cas9 structures and mechanisms. Annual review of biophysics, 46(1), 505-529.
https://doi.org/10.1146/annurev-biophys-062215-010822
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science, 337(6096), 816–821.
https://doi.org/10.1126/science.1225829
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science, 337(6096), 816–821.
https://doi.org/10.1126/science.1225829
Wang, J. Y., & Doudna, J. A. (2023). CRISPR technology: a Decade of Genome Editing Is Only the Beginning. Science, 379(6629).
https://doi.org/10.1126/science.add8643
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 533(7603), 420–424.
https://doi.org/10.1038/nature17946
Kosicki, M., Tomberg, K., & Bradley, A. (2018). Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. Nature biotechnology, 36(8), 765-771.
https://doi.org/10.1038/nbt.4192
Garraway, Levi A., & Lander, Eric S. (2013). Lessons from the Cancer Genome. Cell, 153(1), 17–37.
https://doi.org/10.1016/j.cell.2013.03.002
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65(2), 87–108.
https://doi.org/10.3322/caac.21262
Labrie, S. J., Samson, J. E., & Moineau, S. (2010). Bacteriophage resistance mechanisms. Nature Reviews Microbiology, 8(5), 317–327.
https://doi.org/10.1038/nrmicro2315
Landrum, M. J., Lee, J. M., Benson, M., Brown, G., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Hoover, J., Jang, W., Katz, K., Ovetsky, M., Riley, G., Sethi, A., Tully, R., Villamarin-Salomon, R., Rubinstein, W., & Maglott, D. R. (2015). ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Research, 44(D1), D862–D868.
https://doi.org/10.1093/nar/gkv1222
Lange, V., & Kappel, K. (2022). CRISPR Gene-Therapy: A Critical Review of Ethical Concerns and a Proposal for Public Decision-Making. Canadian Journal of Bioethics, 5(2).
https://doi.org/10.7202/1089787ar
Li, K., Wang, G., Andersen, T., Zhou, P., & Pu, W. T. (2014). Optimization of Genome Engineering Approaches with the CRISPR/Cas9 System. PLoS ONE, 9(8), e105779.
https://doi.org/10.1371/journal.pone.0105779
Lin, S., Staahl, B. T., Alla, R. K., & Doudna, J. A. (2014). Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. ELife, 3.
https://doi.org/10.7554/elife.04766
Lin, Y.-Q., Feng, K.-K., Lu, J.-Y., Le, J.-Q., Li, W.-L., Zhang, B.-C., Li, C.-L., Song, X.-H., Tong, L.-W., & Shao, J.-W. (2023). CRISPR/Cas9-based application for cancer therapy: Challenges and solutions for non-viral delivery. Journal of Controlled Release, 361, 727–749.
https://doi.org/10.1016/j.jconrel.2023.08.028
Liu, N., Xu, S., Yao, Q., Zhu, Q., Kai, Y., Hsu, J. Y., Sakon, P., Pinello, L., Yuan, G.-C., Bauer, D. E., & Orkin, S. H. (2021). Transcription factor competition at the γ-globin promoters controls hemoglobin switching. Nature Genetics, 53(4), 586–586.
https://doi.org/10.1038/s41588-021-00834-x
Liu, W., Li, L., Jiang, J., Wu, M., & Lin, P. (2021). Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precision Clinical Medicine, 4(3), 179–191.
https://doi.org/10.1093/pcmedi/pbab014
Merkle, F. T., Neuhausser, W. M., Santos, D., Valen, E., Gagnon, J. A., Maas, K., Sandoe, J., Schier, A. F., & Eggan, K. (2015). Efficient CRISPR-Cas9-Mediated Generation of Knockin Human Pluripotent Stem Cells Lacking Undesired Mutations at the Targeted Locus. Cell Reports, 11(6), 875–883.
https://doi.org/10.1016/j.celrep.2015.04.007
Misiorek, J. O., Przybyszewska-Podstawka, A., Kałafut, J., Paziewska, B., Rolle, K., Rivero-Müller, A., & Nees, M. (2021). Context matters: NOTCH signatures and pathway in cancer progression and metastasis. Cells, 10(1), 94.
https://doi.org/10.3390/cells10010094
Mohammadzadeh, I., Qujeq, D., Yousefi, T., Ferns, G. A., Maniati, M., & Vaghari‐Tabari, M. (2020). CRISPR /Cas9 gene editing: A new therapeutic approach in the treatment of infection and autoimmunity. IUBMB Life.
https://doi.org/10.1002/iub.2296
Moses, C., Garcia-Bloj, B., Harvey, A. R., & Blancafort, P. (2018). Hallmarks of cancer: The CRISPR generation. European Journal of Cancer, 93, 10-18.
https://doi.org/10.1016/j.ejca.2018.01.002
Nishida, K., Arazoe, T., Yachie, N., Banno, S., Kakimoto, M., Tabata, M., Mochizuki, M., Miyabe, A., Araki, M., Hara, K. Y., Shimatani, Z., & Kondo, A. (2016). Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science, 353(6305).
https://doi.org/10.1126/science.aaf8729
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., ... & Church, G. M. (2013). RNA-guided human genome engineering via Cas9. Science, 339(6121), 823-826.
https://doi.org/10.1126/science.1232033
Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., ... & Restifo, N. P. (2017). Identification of essential genes for cancer immunotherapy. Nature, 548(7669), 537-542.
https://doi.org/10.1038/nature23477
Pawelczak, K. S., Gavande, N. S., VanderVere-Carozza, P. S., & Turchi, J. J. (2017). Modulating DNA Repair Pathways to Improve Precision Genome Engineering. ACS Chemical Biology, 13(2), 389–396.
https://doi.org/10.1021/acschembio.7b00777
Perincheri, S., & Hui, P. (2014). KRAS mutation testing in clinical practice. Expert Review of Molecular Diagnostics, 15(3), 375–384.
https://doi.org/10.1586/14737159.2015.986102
Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y. (2018). Cancer Stem Cells (CSCs) in Drug Resistance and Their Therapeutic Implications in Cancer Treatment. Stem Cells International, 2018, 1–16.
https://doi.org/10.1155/2018/5416923
Prieto-Vila, M., Takahashi, R., Usuba, W., Kohama, I., & Ochiya, T. (2017). Drug Resistance Driven by Cancer Stem Cells and Their Niche. International Journal of Molecular Sciences, 18(12), 2574.
https://doi.org/10.3390/ijms18122574
Rasul, M. F., Hussen, B. M., Salihi, A., Ismael, B. S., Jalal, P. J., Zanichelli, A., Jamali, E., Baniahmad, A., Ghafouri-Fard, S., Basiri, A., & Taheri, M. (2022). Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. Molecular Cancer, 21(1).
https://doi.org/10.1186/s12943-021-01487-4
Rees, H. A., & Liu, D. R. (2018). Base editing: precision chemistry on the genome and transcriptome of living cells. Nature Reviews Genetics, 19(12), 770–788.
https://doi.org/10.1038/s41576-018-0059-1
Rees, H. A., & Liu, D. R. (2018). Base editing: precision chemistry on the genome and transcriptome of living cells. Nature Reviews Genetics, 19(12), 770–788.
https://doi.org/10.1038/s41576-018-0059-1
Rouet, P., Smih, F., & Jasin, M. (1994). Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. Molecular and Cellular Biology, 14(12), 8096–8106.
https://doi.org/10.1128/mcb.14.12.8096
Saber, A., Hiltermann, T. J. N., Kok, K., Terpstra, M. M., de Lange, K., Timens, W., ... & van den Berg, A. (2017). Mutation patterns in small cell and non-small cell lung cancer patients suggest a different level of heterogeneity between primary and metastatic tumors. Carcinogenesis, 38(2), 144-151.
https://doi.org/10.1093/carcin/bgw128
Senís, E., Fatouros, C., Große, S., Wiedtke, E., Niopek, D., Mueller, A.-K., Börner, K., & Grimm, D. (2014). CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. Biotechnology Journal, 9(11), 1402–1412.
https://doi.org/10.1002/biot.201400046
Sheffer, M., Lowry, E., Beelen, N., Borah, M., Amara, S. N. A., Mader, C. C., ... & Mitsiades, C. S. (2021). Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nature Genetics, 53(8), 1196-1206.
https://doi.org/10.1038/s41588-021-00889-w
Sorek, R., Lawrence, C. M., & Wiedenheft, B. (2013). CRISPR-mediated adaptive immune systems in bacteria and archaea. Annual review of biochemistry, 82(1), 237-266.
https://doi.org/10.1146/annurev-biochem-072911-172315
Tzelepis, K., Koike-Yusa, H., De Braekeleer, E., Li, Y., Metzakopian, E., Dovey, O. M., ... & Yusa, K. (2016). A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell reports, 17(4), 1193-1205.
https://www.cell.com/cellreports/fulltext/S2211-1247(16)31335-3
Vaghari-Tabari, M., Majidinia, M., Moein, S., Qujeq, D., Asemi, Z., Alemi, F., Mohamadzadeh, R., Targhazeh, N., Safa, A., & Yousefi, B. (2020). MicroRNAs and colorectal cancer chemoresistance: New solution for old problem. Life Sciences, 259, 118255.
https://doi.org/10.1016/j.lfs.2020.118255
Wang, J., Seebacher, N., Shi, H., Kan, Q., & Duan, Z. (2017). Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. Oncotarget, 8(48), 84559–84571.
https://doi.org/10.18632/oncotarget.19187
Wang, Q., Xiong, J., Qiu, D., Zhao, X., Zheng, Y., Xu, W., Wang, Z., Chen, Q., Panday, S., Li, A., Wang, S., & Zhou, J. (2017). Inhibition of PARP1 activity enhances chemotherapeutic efficiency in cisplatin-resistant gastric cancer cells. Int J Biochem Cell Biol, 92, 164–172.
https://doi.org/10.1016/j.biocel.2017.08.001
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2013). Genetic Screens in Human Cells Using the CRISPR-Cas9 System. Science, 343(6166), 80–84.
https://doi.org/10.1126/science.1246981
Wang, J., Zeng, Z., Li, Z., Liu, G., Zhang, S., Luo, C., Hu, S., Wan, S., & Zhao, L. (2025). The clinical application of artificial intelligence in cancer precision treatment. Journal of Translational Medicine, 23(1), 120.
https://doi.org/10.1186/s12967-025-06139-5
Wang, L., Zheng, W., Liu, S., Li, B., & Jiang, X. (2018). Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy. ChemBioChem.
https://doi.org/10.1002/cbic.201800629
Wood, A. J., Lo, T.-W., Zeitler, B., Pickle, C. S., Ralston, E. J., Lee, A. H., Amora, R., Miller, J. C., Leung, E., Meng, X., Zhang, L., Rebar, E. J., Gregory, P. D., Urnov, F. D., & Meyer, B. J. (2011). Targeted Genome Editing Across Species Using ZFNs and TALENs. Science, 333(6040), 307–307.
https://doi.org/10.1126/science.1207773
Wu, X., Kriz, A. J., & Sharp, P. A. (2014). Target specificity of the CRISPR-Cas9 system. Quantitative Biology, 2(2), 59–70.
https://doi.org/10.1007/s40484-014-0030-x
Yamauchi, T., Masuda, T., Canver, M. C., Seiler, M., Semba, Y., Shboul, M., Al-Raqad, M., Maeda, M., Schoonenberg, V. A. C., Cole, M. A., Macias-Trevino, C., Ishikawa, Y., Yao, Q., Nakano, M., Arai, F., Orkin, S. H., Reversade, B., Buonamici, S., Pinello, L., & Akashi, K. (2018). Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS. Cancer Cell, 33(3), 386-400.e5.
https://doi.org/10.1016/j.ccell.2018.01.012
Yang, X., Boehm, J. S., Yang, X., Salehi-Ashtiani, K., Hao, T., Shen, Y., ... & Root, D. E. (2011). A public genome-scale lentiviral expression library of human ORFs. Nature methods, 8(8), 659-661.
https://doi.org/10.1038/nmeth.1638
Yang, Y., Xu, J., Ge, S., & Lai, L. (2021). CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research. Frontiers in Medicine, 8.
https://doi.org/10.3389/fmed.2021.649896
Yin, H., Xue, W., & Anderson, D. G. (2019). CRISPR–Cas: a tool for cancer research and therapeutics. Nature reviews Clinical oncology, 16(5), 281-295.
https://doi.org/10.1038/s41571-019-0166-8
Zhang, H.-L., Hu, B.-X., Ye, Z.-P., Li, Z.-L., Liu, S., Zhong, W.-Q., Du, T., Yang, D., Mai, J., Li, L.-C., Chen, Y.-H., Zhu, X.-Y., Li, X., Feng, G.-K., Zhu, X.-F., & Deng, R. (2024). TRPML1 triggers ferroptosis defense and is a potential therapeutic target in AKT-hyperactivated cancer. Science Translational Medicine, 16(753).
https://doi.org/10.1126/scitranslmed.adk0330
Zhang, M., Eshraghian, E. A., Jammal, O. A., Zhang, Z., & Zhu, X. (2021). CRISPR technology: The engine that drives cancer therapy. Biomedicine & Pharmacotherapy, 133, 111007.
https://doi.org/10.1016/j.biopha.2020.111007
Zhao, Y., Shen, M., Wu, L., Yang, H., Yao, Y., Yang, Q., Du, J., Liu, L., Li, Y., & Bai, Y. (2023). Stromal cells in the tumor microenvironment: accomplices of tumor progression? Cell Death and Disease, 14(9).
https://doi.org/10.1038/s41419-023-06110-6
Zimta, A.-A., Cenariu, D., Irimie, A., Magdo, L., Nabavi, S. M., Atanasov, A. G., & Berindan-Neagoe, I. (2019). The Role of Nrf2 Activity in Cancer Development and Progression. Cancers, 11(11).
https://doi.org/10.3390/cancers11111755
Zischewski, J., Fischer, R., & Bortesi, L. (2017). Detection of on-target and off-target mutations generated by CRISPR/Cas9 and other sequence-specific nucleases. Biotechnology Advances, 35(1), 95–104.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
